Renalytix Clinical Advisory Board Formed to Support Broadening Use of KidneyintelX.dkd

World leading, multi-disciplinary experts advise on adoption of FDA authorized KidneyintelX.dkd across 14 million US patients with diabetes and chronic kidney disease

LONDON and SALT LAKE CITY, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces the launch of its Clinical Advisory Board, a world-leading, multi-disciplinary clinical group, to help advance the use of FDA authorized kidneyintelX.dkd in mitigating uncontrolled kidney disease progression and guiding early stage treatment strategies for the estimated 14 million Americans with diabetic kidney disease.¹

Commenting on the board’s formation, Dr. Ralph DeFronzo said, “Now is the time when we can change the entire conversation around kidney disease from the current focus on better management of dialysis and transplant to preventative medicine and preserving kidney health early on. The confluence of new diagnostic technology, such as kidneyintelX.dkd, and new effective drug therapies, including SGLT2 inhibitors, has swung the door wide open to prevent millions of people from experiencing the life changing effects of uncontrolled kidney disease. We must now act deliberately to make sure primary care doctors, nurse practitioners and physician assistants across the U.S., and around the world, have access to these clinical advances.”

Diabetic kidney disease (DKD) is a complication in up to 40% of patients with type 2 diabetes² and in approximately 60% of patients aged 65 years and older³. In multiple published studies, KidneyIntelX in vitro prognostic technology has shown the ability to provide reliable and actionable information to guide care and enable primary care physicians to recognize and act on early-stage kidney risk when therapies are most effective, thereby improving kidney health.

The Clinical Advisory Board members include:

• Stephen Brunton, MD, FAAFP, CDCES; University of North Carolina, Executive Director of Primary Care Metabolic Group (PCMG) and Editor-in-Chief of Clinical Diabetes
• Matthew Jay Budoff, MD, FACC, FAHA; David Geffen School of Medicine at UCLA and Endowed Chair of Preventive Cardiology at Harbor-UCLA Medical Center
• Barry I. Freedman, MD, FACP; John Felts Distinguished Professor and Chief of the Nephrology Section at Wake Forest University School of Medicine
• Ralph A. DeFronzo, MD; Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Deputy Director of the Texas Diabetes Institute
• Holly J. Mattix-Kramer MD, MPH; Division of Nephrology and Hypertension at Loyola University Chicago, Associate Director of Research for the Medicine Service Line and Founding Director of the Hines VA Serwa Research Center on Aging
• Javier Morales MD, FACP, FACE; Vice President and Principal Clinical Trials Investigator at Advanced Internal Medicine Group
• Joseph A. Vassalotti MD; Chief Medical Officer of the National Kidney Foundation (NKF) and Clinical Professor of Medicine in the Division of Nephrology at Icahn School of Medicine at Mount Sinai
• Eugene E. Wright Jr., MD; Duke University Medical Center and Medical Director for Performance Improvement at the Charlotte Area Health Education Center

Renalytix is dedicated to promoting early action to enhance the quality of life for individuals impacted by diabetic kidney disease with its risk assessment test, kidneyintelX.dkd. KidneyintelX.dkd is the only FDA approved risk assessment test, developed from the KidneyIntelX technology platform which has achieved broad scale reimbursement, for identifying risk for rapid kidney disease progression, thus enabling clinicians to intervene early with guideline-recommended actions. Clinical actions are most effective for preserving kidney and cardiovascular health in DKD stages 1-3 before significant and irreversible kidney function loss has occurred.